Hysterecomy fails to offer better disease control

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

A modified radical hysterectomy (class II) did not improve locoregional control and survival compared with simple extrafascial abdominal hysterectomy (class I). Investigators from University of Milano-Bicocca in Monza, Italy, randomized 520 patients with stage I endometrial cancer to class I or class II surgery. They found that the median length of parametria and vagina removed were 15 mm and 5 mm respectively for class I hysterectomy vs 20 mm and 15 mm for class II hysterectomy (P > .001). Operating time and blood loss were statistically significantly higher for class II hysterectomy. Five-year disease-free survival and overall survival was 87.7% and 88.9% respectively in the class I arm, and 89.7% and 92.2% in the class II arm (Ann Surg Oncol online, October 16, 2009).

A modified radical hysterectomy (class II) did not improve locoregional control and survival compared with simple extrafascial abdominal hysterectomy (class I). Investigators from University of Milano-Bicocca in Monza, Italy, randomized 520 patients with stage I endometrial cancer to class I or class II surgery. They found that the median length of parametria and vagina removed were 15 mm and 5 mm respectively for class I hysterectomy vs 20 mm and 15 mm for class II hysterectomy (P > .001). Operating time and blood loss were statistically significantly higher for class II hysterectomy. Five-year disease-free survival and overall survival was 87.7% and 88.9% respectively in the class I arm, and 89.7% and 92.2% in the class II arm (Ann Surg Oncol online, October 16, 2009).

Recent Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.